Abstract
| Original language | English |
|---|---|
| Title of host publication | Advances in Treatment of Hepatitis C and B |
| Publisher | InTech |
| ISBN (Electronic) | 978-953-51-2994-3 |
| ISBN (Print) | 978-953-51-2993-6 |
| DOIs | |
| Publication status | Published - Mar 8 2017 |
Fingerprint
Keywords
- hepatitis C virus
- viral entry
- antivirals
- entry inhibitors
- monoclonal antibodies
- small molecules
- therapeutic plasma products
Cite this
Strategies to Preclude Hepatitis C Virus Entry. / Burnouf, Thierry Pierre Robert; Liu, Ching Hsuan; Lin, Liang-Tzung.
Advances in Treatment of Hepatitis C and B. InTech, 2017.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Strategies to Preclude Hepatitis C Virus Entry
AU - Burnouf, Thierry Pierre Robert
AU - Liu, Ching Hsuan
AU - Lin, Liang-Tzung
PY - 2017/3/8
Y1 - 2017/3/8
N2 - Without a preventive vaccine, hepatitis C virus (HCV) remains an important pathogen worldwide with millions of carriers at risk of end-stage liver diseases. Despite the introduction of novel direct-acting antivirals (DAAs), resistance problems, challenges with the difficult-to-treat populations and high costs limit the widespread application of these drugs. Antivirals with alternative mechanism(s) of action, such as by restricting viral entry or cell-to-cell spread, could help expand the scope of antiviral strategies for the management of hepatitis C. Transfusion-associated HCV infection remains another issue in endemic and resource-limited areas around the world. This chapter describes some of the latest developments in antiviral strategies to preclude HCV entry, such as through monoclonal antibodies and small molecules, as well as measures to enhance the safety of therapeutic plasma products in blood transfusion.
AB - Without a preventive vaccine, hepatitis C virus (HCV) remains an important pathogen worldwide with millions of carriers at risk of end-stage liver diseases. Despite the introduction of novel direct-acting antivirals (DAAs), resistance problems, challenges with the difficult-to-treat populations and high costs limit the widespread application of these drugs. Antivirals with alternative mechanism(s) of action, such as by restricting viral entry or cell-to-cell spread, could help expand the scope of antiviral strategies for the management of hepatitis C. Transfusion-associated HCV infection remains another issue in endemic and resource-limited areas around the world. This chapter describes some of the latest developments in antiviral strategies to preclude HCV entry, such as through monoclonal antibodies and small molecules, as well as measures to enhance the safety of therapeutic plasma products in blood transfusion.
KW - hepatitis C virus
KW - viral entry
KW - antivirals
KW - entry inhibitors
KW - monoclonal antibodies
KW - small molecules
KW - therapeutic plasma products
U2 - 10.5772/65470
DO - 10.5772/65470
M3 - Chapter
SN - 978-953-51-2993-6
BT - Advances in Treatment of Hepatitis C and B
PB - InTech
ER -